Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 1 of 38                                                       Version 1.0, 22 FEB 2016  
TITLE PAGE  
 
 
 
Protocol Number:  C-16-EV10  
Protocol Title:  A Single -Center Open -Label Study of  1064 nm Nd:YAG for 
Nonablative Skin Rejuvenation  
 
Sponsor:  
 Cutera, Inc.  
3240 Bayshore Boulevard  
Brisbane, CA 94005  
Telephone: 1 -415-657-5722  
Fax:  1 -415-715-3722 
Contact:  Gayle Weiss  
Email:  gweiss@cutera.com  
 
Principal Investigator:   
 
 
 
Version, Date:  Version 1.0  Dated  February 22, 2016  
 
 
   
Statement of Compliance  
The study will be cond ucted in accordance with the design and specific provisions of this IRB approved protocol, in 
accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent 
with Good Clinical Practice (GCP) and the applicable regulatory requirement(s).  
 
   
NOTE:   The confidential information in the following document is provided to you as an Investigator, potential Investigator, or cons ultant for 
review by you, your staff, and applicable Institutional Review Board. B y accepting this document, you agree that the information contained 
herein will not be disclosed to others, without written authorization from Cutera, Inc. except to the extent necessary to obtain informed 
consent from those persons to whom the device will  be administered.  
 
    

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 2 of 38                                                       Version 1.0, 22 FEB 2016  
Protocol Signature Page  – Principal Investigator  
 
 
PROTOCOL C-16-EV 10 
 
 
Study Title:   A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin 
Rejuvenation  
 
 
Protocol Version 1.0 , Dated February 22 , 2016  
 I hav e received and read the protocol dated February 22 , 2016 and agree to adhere to the requirements. 
I am aware that my adherence to the above protocol is mandatory and that any changes in the protocol or informed consent form must first be approved by Cutera, Inc. and the Institutional Review Board, except those changes necessary to eliminate apparent immediate hazards to subjects.  I will provide copies of this protocol and all pertinent information to the study personnel under my supervision. I will discuss  this 
material with them and ensure they are fully informed regarding their role in the study. I will ensure that the study is conducted in compliance with the protocol, Good Clinical Practice (GCP), and all applicable regulatory requirements, and with the  reviewing Institutional Review Board (IRB) requirements. I agree to 
commence this study only after documented IRB approval is obtained.  
  
 
 
Principal 
Investigator      
  Signature   Date  
 
 
     
  Printed Name    
 
   
 
  

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 3 of 38                                                       Version 1.0, 22 FEB 2016 Table of Contents  
Protocol Summary  .......................................................................................................................................... 6  
1 PURPOSE  ................................................................................................................................................ 7  
2 BACKGROUND INFORMATION  ............................................................................................................... 7  
2.1 Photo -Rejuvenation  ............................................................................................................................ 7  
2.2 Study Device  ........................................................................................................................................ 7  
3 STUDY OBJECTIVES  ................................................................................................................................. 8  
4 STUDY DESIGN  ........................................................................................................................................ 8  
4.1 Study Endpoints  .................................................................................................................................. 9  
4.1.1  Efficacy endpoints  ........................................................................................................................... 9  
4.1.1.1  Primary Efficacy Endpoint  ............................................................................................................ 9  
4.1.1.2  Secondary Efficacy Endpoints  ...................................................................................................... 9  
4.1.2  Safety Endpoint  ............................................................................................................................... 9  
4.2 Study Duration  .................................................................................................................................... 9  
4.3 Study Effectiveness Assessments  ........................................................................................................ 9  
4.3.1  Blinded Assessments  ....................................................................................................................... 9  
4.3.1.1  Blinded Reviewer’s Global Assessment of Improvement  ............................................................. 9  
4.3.1.2  Blinded Reviewer’s Assessment of Photoagin g ......................................................................... 10  
4.3.2  Investigator Assessments .............................................................................................................. 10  
4.3.2.1  Investigator’s Global Assessment of Improvement  ................................................................... 10  
4.3.3  Subject Assessments  ..................................................................................................................... 10  
4.4 Exploratory Assessments  ........................................................................................................... 11  
4.4.1  Fitzpatrick Wrinkle Classificatio n .................................................................................................. 11  
4.4.2  Skin Texture Assessment  ............................................................................................................... 11  
4.5 Study Safety Assessments .......................................................................................................... 11  
4.5.1  Incidence and Severity of Adverse Events:  ................................................................................... 11  
4.5.2  Treatment -related Discomfort  ...................................................................................................... 11  
4.6 Photographs  .................................................................................................................................. 11  
4.7 Study Discontinuation  ................................................................................................................... 12  
4.8 Investigator Selection  .................................................................................................................... 12  
5 STUDY POPULATION  ............................................................................................................................. 12  
5.1 Study Subject Recruitment and Selection  ..................................................................................... 12  
5.1.1  Inclusion Criteria  .................................................................................................................... 12  
5.1.2  Exclusion Criteria  .................................................................................................................... 13  

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 4 of 38                                                       Version 1.0, 22 FEB 2016 5.2 Subject Numbering  ........................................................................................................................ 14  
5.3 Subject Discontinuation Criteria .................................................................................................... 14  
6 STUDY PROCEDURES  ............................................................................................................................ 14  
6.1 Screening / Enrollment  ...................................................................................................................... 14  
6.2 Laser Treatment # 1  ........................................................................................................................... 15  
6.2.1  Pre-Treatment Procedures  ............................................................................................................. 15  
6.2.2  Global 1064nm Nd:YAG Laser Genesis Treatment  - Treatment #1 - #6 ..................................... 15  
6.2.3  Post- Treatment Procedures  ............................................................................................................ 16  
6.3 Follow- Up Visits  ............................................................................................................................... 16  
6.4 Biopsy Samples  .............................................................................................................................. 17  
6.5 Biopsy Procedure (if performed) ...................................................................................................... 17  
6.6 Biopsy Suture Removal Visit (as applicable)  .................................................................................... 17  
7 ADVE RSE DEVICE EFFECTS  .................................................................................................................... 18  
7.1 Definitions  ......................................................................................................................................... 18  
7.1.1  Adverse Device Effect  ................................................................................................................... 18  
7.1.2  Serious Adverse Device Effect  ...................................................................................................... 18  
7.1.2.1  Anticipated Serious Adverse Device Effect (ASADE)  ................................................................ 18  
7.1.2.2  Unanticipated Ser ious Adverse Device Effect (USADE/UADE)  ............................................... 18  
7.2 Recording ADEs and SADEs ............................................................................................................ 21  
7.3 Follow-up of Subjects after ADEs and SADEs: ............................................................................... 21  
8 POTENTIAL RISKS / BE NEFITS  ............................................................................................................... 21  
8.1 Potential Risks  ................................................................................................................................... 21  
8.2 Potential Benefits  .............................................................................................................................. 22  
9 RISK MANAGEMENT  ............................................................................................................................. 22  
10 DATA ANALYSIS PLAN  ............................................................................................................................ 23  
10.1  Sample  Size  ....................................................................................................................................... 23  
10.2  Demographics and Subject Characteristics at Baseline .................................................................... 23  
10.3  Statistical Analysis Methods  ............................................................................................................. 23  
10.3.1  Analysis Sets  ................................................................................................................................. 23  
10.3.2  Analysis of Primary Endpoint ....................................................................................................... 23  
10.3.3  Analyses of Secondar y Endpoints ................................................................................................. 23  
10.3.4  Safety Analyses  ............................................................................................................................. 23  
11 SUBJECT PAYMENT  ............................................................................................................................... 24  
12 STUDY MANAGEMENT AND ADMINISTRATIVE PROCE DURES  ............................................................. 24  
12.1  Training and Monitoring ................................................................................................................... 24  

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 5 of 38                                                       Version 1.0, 22 FEB 2016 12.2  Informed Consent .............................................................................................................................. 24  
12.3  Protocol Compliance ......................................................................................................................... 25  
12.3.1  Protocol Amendments  .................................................................................................................... 25  
12.3.2  Protocol Deviations  ....................................................................................................................... 25  
12.4  Study Personnel ................................................................................................................................. 25  
12.5  Disclosure of Financial Interest  ........................................................................................................ 25  
12.6  Data Collection, Record Keeping and Storage ................................................................................. 26  
13 SUBJECT CONFIDENTIAL ITY .................................................................................................................. 27  
14 PUBLICATION POLICY ............................................................................................................................ 27  
REFERENCES  ............................................................................................................................................. 29  
Appendix 1: Study Schedule ........................................................................................................................ 31  
Appendix 2: Pain Rating Scale .................................................................................................................... 32  
Appendix 3: Fitzpatrick Wrinkle Classification System  .............................................................................. 33  
Appendix 4: Fitzpatrick Skin Type Classification  ....................................................................................... 34  
Appendix 5:  Before and After Treatment Instructions ............................................................................... 35  
Appendix 6:  Before and After Biopsy Instructions .................................................................................... 36  
Appendix 7:  Subject Questionnaire ............................................................................................................ 37  
 
 
                      

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 6 of 38                                                       Version 1.0, 22 FEB 2016 Protocol Summary  
 
Title  A Single -Center Open -Label Study of  1064 nm  Laser for 
Nonablative Skin Rejuvenation  
Objective 
 To evaluate the efficacy and sa fety of the  Cutera excel  V Laser 
Genesis/  1064 nm  laser for sk in rejuvenation.  
Study Design  A single -center prospective, open -label uncontrolled study.  
Enrollment  15 subjects  
Primary Endpoint  • Degree of improvement at 12  weeks  post -final treatment  as 
assessed by independent blinded reviewers (Physician’s Global 
Assessment).  
Secondary Endpoints  
 
 
 
  
•  
 
  
 
  
 
  
  
 
  
  
  
 
 
Subject Population  Female or male subjects, age 35 to 55 years, Fitzpatrick skin type s I-IV 
Planned Schedule  First subject enrolled:  March 15, 2016  
Last subject last visit:   January 15, 2017  
 
 
 
   

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 10 of 38                                                       Version 1.0, 22 FEB 2016 post -final treatment photographs will be randomized such that the baseline photograph will be randomly 
assigned to the left or right side of the page. The order of subject photograph pairs will also be 
randomized. The reviewers will be blinded to the treatment parameters used, the subject data, the temporal order of photographs (before and after), and follow -up time point.  
 The reviewers will be asked to first determin e the temporal order of each photograph pair, then rate the 
degree of improvement observed in the post -treatment photograph using the Physician’s Global 
Assessment of Improvement Scale:  
    4 = Very Significant Improvement  
   3 = Significant Improv ement  
   2 = Moderate Improvement  
   1 = Mild Improvement  
   0 = No Change  
4.3.1.2   
 
4.3.2  
  
   
 
 
    
    
    
    
    
  
  
   
     
    
  
  
    
   

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 11 of 38                                                       Version 1.0, 22 FEB 2016 4.3.3.2   
 
 
 
  
 
 
 
4.4  
  
  
 
  
 
 
4.5 Study Safety A
ssessments  
4.5.1 Incidence and Severity of Adverse Events:   
Following the first laser  treatment, adverse device effects (ADEs) will be assessed post -treatment and at 
each subsequent subject visit using the following  scale:  
 
1= mild: requires minimal or no treatment and does not interfere with the Subject’s daily activities.  
2= moderate: may cause some interference with functioning.  
3= severe: interrupts Subject’s usual daily activity and may require treatment.  
4.5.2 Treat ment -related Discomfort  
Subjects will be asked to rate the average amount of discomfort experienced during laser  treatment 
using the Pain Rating Scale found in Appendix 2. 
4.6 Photographs  
Standardized digital photographs will be taken of each subject’s face  at baseline, prior to all laser 
treatments and at both follow -up visits . Any jewelry will be removed from the area being photographed. 
Hair will be pulled away from the face with a headband and subject will have recently cleansed skin. Facial 
photographs wil l be obtained from 3 angles: with the subject facing forward, 45° to the right  and 45° to 
the left. Photographs will be taken in the same windowless room equipped with adequate lighting. The room lighting, camera positioning and subject positioning should be consistent for all study visit 
photographs. Digital camera settings should remain the same for all photographs and the highest 
resolution settings should be utilized.  

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 12 of 38                                                       Version 1.0, 22 FEB 2016 4.7 Study Discontinuation  
The sponsor (Cutera, Inc.) has the right to terminate this stud y at any time.  Reasons for terminating the 
study may include, but are not limited to, the following: incidence or severity of adverse events in this or 
other studies indicates a potential health hazard to subjects; subject enrollment is unsatisfactory; number of protocol deviations is unacceptable; data recording is inaccurate or incomplete; or questionable study site compliance with ICH -E6, Good Clinical Practice.  
4.8 Investigator Selection  
The Investigator  will be invited to participate in the study based on his/her  medical specialty, experience 
conducting clinical research studies and experience in the use of light -based devices for aesthetic 
indications. Access to potential study subjects and the Investigator’ s sincere interest in this study along 
with expressed willingness to cooperate with the study process and requirements will also be considered.  
5 STUDY POPULATION  
5.1 Study Subject Recruitment and Selection  
Twenty  male or female subjects, ages 35 to 55, with Fitzpatrick Skin Type I -IV (see Appendix 4 for ski n type 
classification) who desire laser treatment for facial wrinkles or photo -rejuvenation will be studied. 
Subjects will be recruited to participate from the local population. Subjects may also be recruited from the Investigator’s existing patient database or from patients who present themselves to the study site requesting treatment. Only subjects who meet all eligibility criteria and who provide written informed consent will be enrolled into the study.  
 Each subject will be evaluated by the Investigator  to assess his/her suitability for entry into the study 
according to the following inclusion and exclusion criteria.  
5.1.1 Inclusion Criteria  
To be included in the study, subjects must meet all of the following Inclusion Criteria:  
1.  Female or Male, 35 to 55 year s of age (inclusive).  
2.  Fitzpatrick Skin Type I – IV (Appendix 4). 
3.  Desires non-invasive and non-ablative treatment of skin-aging or photo -rejuvenation of 
the skin.  
4.  Have signs  of moderate skin aging, including presence of mild to moderate rhytides 
aroun d eyes and upper lip, multiple lentigines, diffuse erythema or telangiectasia, and a 
score between 4 and 7 (inclusive) on the Fitzpatrick Wrinkle Classification Scale 
(Appendix 3).   
5.  Subject must be able to read, understand and sign the Informed Consent Form.  
6.  Must be willing and able to adhere to the treatment and follow -up schedule and post -
treatment care instructions.  
7.  Willing to have very limited sun exposure and use an approved sunscreen of SPF 30 or 
higher on the treatment area every day for the d uration of the study, including the 
follow -up period . 
8.  Willing to have digital photographs taken of the treatment area and agree to use of 
photographs for presentation, educational or marketing purposes.  

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 13 of 38                                                       Version 1.0, 22 FEB 2016 9.  Agree to not undergo any other procedure(s) for s kin rejuvenation during the study , 
including b ut not limited to chemical peel, laser and  light based  device treatment, and 
home -use device treatment . 
10.  Agree to not undergo any injection of botulinum toxin, collagen, hyaluronic acid filler or 
other dermal filler during the study . 
11.  Post -menopausal or surgically sterilized, or using a medically acceptable form of birth 
control at least 3 months prior to enrollment and during the entire course of the study, 
and no plans to become pregnant or to father a child  for the duration of the study.  
 
5.1.2 Exclusion Criteria  
Subjects will be excluded from the study if they meet any of the following Exclusion Criteria:  
 
1.  Participation in a clinical trial of another device or drug within 6 months prior to 
enrollment or during the study . 
2.  Any type of prior cosmetic treatment to the target area within 6 months of study 
participation, such as laser or light -based procedures or surgery.  
3.  Prior injection  to the face  of botulinum toxin, collagen, hyaluronic acid filler or other 
dermal filler within 6 months of study participation , as applicable . 
4.  Systemic use of retinoid, such as isotretinoin, or corticosteroid, as applicable, within 6 
months of study participation.  
5.  Use of topical medications on the face, such as antibiotics, be nzoyl peroxide, retinoid s 
(isotretinoin) , corticosteroid s, hydroquinone , or products containing dihydroxyacetone 
or alpha -hydroxy with concentration > 8%, within 1 month of participation.  
6.  History of malignant tumors in the target area.  
7.  Skin abnormaliti es in the target area, e.g., cuts, scrapes, wounds, scars, large moles.  
8.  Pregnant and/or breastfeeding.  
9.  Having an infection, dermatitis or a rash in the treatment area.  
10.  Significant concurrent illness, such as diabetes mellitus or cardiovascular disea se, e.g., 
uncontrolled hypertension.  
11.  Suffering from coagulation disorders , or taking prescription anticoagulation medication  
which  might make study participation unsafe  according to Investigator’s discreti on. 
12.  History of keloid scarring, hypertrophic sc arring or of abnormal wound healing.  
13.  History of immunosuppression/immune deficiency disorders or currently using 
immunosuppressive medications.  
14.  History of vitiligo, eczema, or psoriasis.  
15.  History of connective tissue disease, such as systemic lupus erythematosus or 
scleroderma.  
16.  History of seizure disorders due to light.  
17.  Any use of medication that is known to increase sensitivity to light according to 
Investigator’s discretion.  
18.  History of disease stimulated by heat, such as recurrent herpes sim plex and/or herpes 
zoster (shingles) in the treatment area, unless treatment is conducted following a 
prophylactic regimen  

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 14 of 38                                                       Version 1.0, 22 FEB 2016 19.  History of radiation to the treatment area or undergoing systemic chemotherapy for the 
treatment of cancer.  
20.  History of pigmentar y disorders, particularly tendency for hyper - or hypo -pigmentation.  
21.  Anytime in life, having have used gold therapy (gold salts) for disorders such as 
rheumatologic disease or lupus.  
22.  Excessively tanned in areas to be treated or unable/unlikely to refrai n from tanning during 
the study.  
23.  Current smoker or history of smoking within 6 months of study participation.  
24.  As per the Investigator’s discretion, any physical or mental condition which might make 
it unsafe for the subject to participate in this stud y. 
5.2 Subject Numbering  
If a subject meets the study eligibility criteria and is willing to participate, the subject will be assigned a 
study subject identification number. This number is comprised of a sequential subject number and the subject initials (fi rst and last names).  
5.3 Subject Discontinuation Criteria  
If possible, every subject should remain in the study until completion of the required follow -up period. 
However, participation in this study is completely voluntary and a subject can choose to withdraw  from 
the study at any time.  Decision to withdraw will not affect or prejudice the subject’s continued medical care in any way. In those instances, the investigator will attempt to obtain a final clinical assessment and 
an adverse device effect evaluation  for the subject prior to this withdrawal. A subject will be considered 
lost to follow -up only after three unsuccessful, documented attempts to contact the subject have been 
made.   
 
In addition, a subject can be discontinued for any of the following reasons: the Principal Investigator 
decides that continuing in the study would not be in the subject’s best interest, a subject is noncompliant with the protocol, a subject has a serious reaction to the treatment, a subject develops any of the exclusion criteria during the study period or the study is stopped by the study sponsor.  
6  
 
  
 
 
 
 
 
 
  

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 17 of 38                                                       Version 1.0, 22 FEB 2016  
 
 
 
  
 
   
 
  
 
  
   
 
 
 
  
 
 
  
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 18 of 38                                                       Version 1.0, 22 FEB 2016   
 
7 ADVERSE DEVICE EFFEC TS  
7.1 Definitions  
  
 
 
 
 
  
 
  
 
 
 
  
   
  
  
  
  
 
  
  
    
  
  
    
 
 

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm Laser for Nonablative Skin Rejuvenation ” 
Confidentia l and Proprietary  Page 20 of 38                                                       Version 1.0, 22 FEB 2016 

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 22 of 38                                                       Version 1.0, 22 FEB 2016   
   
    
    
    
  
    
    
    
    
  
   
    
 
 
    
 
    
 
 
    
    
 
 
 
 
 
8.2 Potential Benefits  
The subjects may or may not benefit from the treatment with the study device. Potential benefit of laser 
treatment for photo -rejuvenation is improved appearance of skin, diminished appearance of rhytides, 
improvement in telangiectasia and lightening of lentigines. There is no guarantee of success.  
9 RISK MANAGEMENT  
The investigator  participating in this study was  chosen based on extensive and safe experience with the 
use of lasers in dermatology applications. This is the most critical element in managing subject risk. In addition, study investigators will be trained on the use of the Cutera excelV  laser  system by a 
representative of Cutera.  

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 23 of 38                                                       Version 1.0, 22 FEB 2016 10  DATA ANALYSIS PLAN  
10.1 Sample Size 
Up to  subjects  will be enrolled i n this safety and efficacy study.  
10.2 Demographics and Subject Characteristics at Baseline  
Subject demographics, medical history, concomitant medications will be tabulated and summarized 
descriptively.  
10.3 Statistical Analysis Methods  
10.3.1 Analysis Sets  
The efficacy an alysis set will include all subjects who received at least one laser treatment session and 
complete a follow -up visit. The safety analysis set will include all subjects enrolled in the study who had 
at least one laser treatment session.  
 Missing data will not be imputed for efficacy or safety endpoints.  
10.3.2 Analysis of Primary Endpoint  
Formal statistical analysis is not planned for this study. The  primary efficacy endpoint data, blinded 
reviewer degree of improvement at 12 weeks  post -final treatment, will be su mmarized descriptively.  
  
  
 
 
  
 
  
 
  
 
   
  
  
10.3.4 Safety Analyses  
Safety variables will be analyzed descriptively.  
 The safety variables for this study are:  
 
1. Subject discomfort (pain) during treatment (to be des criptively displayed).  
 

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 24 of 38                                                       Version 1.0, 22 FEB 2016 2. Incidence and severity of adverse effects during study duration (to be displayed descriptively 
as counts and frequency distributions).  
 Enrolled subjects who received at least one treatment will be included in the safety analyses.  Device -
related and procedure -related adverse effects (AEs) and subjects who prematurely terminate from the 
study due to an adverse device effect, including the treatment- related pain ratings, as reported on case 
report forms will be tabulated and analyzed . For a given AE term, counting will be done by subject, not by 
event, i.e. for a subject reporting the same AE more than once, the event will be counted only once, at the 
most severe and most -related occurrence.  The number and percentage of subjects expe riencing each AE 
Term will be descriptively summarized. Statistical hypothesis testing will not be performed for safety data.  
11    
 
  
   
12   S 
TUD
Y MANAGEMENT AND  ADMINISTRATIVE PROCE DURES  
 
  
  
 
     
 
 
       
  
 
    
  

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 25 of 38                                                       Version 1.0, 22 FEB 2016  
 
  
 
 
  
  
 
   
 
12.3 Protocol Compliance  
The principal investigator must comply with all terms of the protoc ol. 
12.3.1 Protocol Amendments  
Neither the principal investigator nor the sponsor will modify or alter this protocol without first obtaining the concurrence of the other party (with the exception of amendments which involves mitigating a medical emergency or imme diate health risk to the subject). The party initiating an amendment must 
confirm it clearly in writing and it must be signed and dated by the sponsor and the principal investigator. IRB approval must be obtained before implementation of an amendment.  
12.3.2  Protocol Deviations  
All protocol deviations must be clearly described on the case report form (i.e., Cutera Protocol Deviation Form). Deviations from the protocol may include but are not limited to subject’s failure to attend scheduled visit during a visit window, use of out of range treatment parameters and incomplete or incorrect study procedures. Any medical emergency or immediate health risk to the subject which results in a protocol deviation and must be reported to the sponsor within 5 working days  
 Significant protocol deviations must be reported to IRB according to their policies.  
12.4 Study Personnel  
Prior to the start of the study, the investigator must supply the sponsor with a list of the names and curricula vitae that describe the professional backgroun ds of the clinically responsible study investigators 
(principal, sub -investigators), research nurses, and other possible participants (e.g. medical doctor, nurse, 
etc.).  
12.5 Disclosure of Financial Interest  
Each investigator [principal and sub -investigator(s)]  is required to disclose sufficient accurate financial 
information to the sponsor, to allow sponsor to submit complete and accurate certification or disclosure statements.  

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 26 of 38                                                       Version 1.0, 22 FEB 2016 12.6 Data Collection, Record Keeping and Storage 
The principal investigator is responsibl e for assuring that all study records including case report forms 
 
  
 
 
 
 
 
   
 
 
  
  
  
 
 
  
 
 
  
 
 
 
 
 
 
  
  
 
 
  
 
 
  
 
  
 
 
    
  
 

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 27 of 38                                                       Version 1.0, 22 FEB 2016  
 
 
 
  
13   SUBJE
CT CONFIDENTIAL ITY 
This study preserves the confidentiality of all subjects under the Health Insurance Portability and Accountabil ity Act of 1996 (HIPAA) Privacy Rule. The following safeguards will be in place to protect the 
privacy of the individuals who are the subjects of the health information to be used in the research and the confidentiality of that information:   
 
   
  
 
      
 
  
 
 
    
 
   
14   PUB
LICA
TION POLICY  
The investigator shall have the right to publish the results of the s tudy. Unless mutually agreed upon in 
writing, prior to submission for publication of any manuscript, poster, presentation, abstract or other written or oral material describing the results of the study, the investigator shall allow sponsor to review manusc ript, poster presentation, abstract or other written or oral material which describes the results of 
the study for the purpose only of determining if any patentable information is disclosed. At the sponsor’s request, the investigator shall withhold any publication or presentation to permit sponsor to seek patent protection and to remove any confidential information from all publications.   

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 29 of 38                                                       Version 1.0, 22 FEB 2016  
 
 
 
 
  
 
 
  
 
  
 
  
 
 
  
 
  
 
  
 
 
  
 
  
 
  
 
  
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 30 of 38                                                       Version 1.0, 22 FEB 2016   
 
  
 
 
  
 
  
 
  
 
 
         
 
             
 
       
 

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 31 of 38                                                       Version 1.0, 22 FEB 2016 

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 32 of 38                                                       Version 1.0, 22 FEB 2016  
 
 
 
 
 
 
  
 
 
   
 
  

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 33 of 38                                                       Version 1.0, 22 FEB 2016  
  

Cutera, Inc.  
Protocol #  C-16-EV10 
“A Single -Center Open -Label Study of 1064 nm  Laser for Nonablative Skin Rejuvenation ” 
 
Confidentia l and Proprietary  Page 34 of 38                                                       Version 1.0, 22 FEB 2016  
     
 
 
